Atlas Trials

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Clinical trial NCT03235245 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03235245
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Stage III MelanomaStage IV Melanoma
Start date
2018-10-30
Primary completion
2023-10-24
Enrollment
271

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.